166 related articles for article (PubMed ID: 32506471)
1. Prevalence of insulin as a first-line therapy and associated factors in people with type 2 diabetes in German primary care practices.
van den Boom L; Kaiser M; Kostev K
Diabet Med; 2020 Aug; 37(8):1333-1339. PubMed ID: 32506471
[TBL] [Abstract][Full Text] [Related]
2. Patterns of anti-diabetic medication use in patients with type 2 diabetes mellitus in England and Wales.
Datta-Nemdharry P; Thomson A; Beynon J; Donegan K
Pharmacoepidemiol Drug Saf; 2017 Feb; 26(2):127-135. PubMed ID: 27642000
[TBL] [Abstract][Full Text] [Related]
3. Diabetes treatment in people with type 2 diabetes and schizophrenia: Retrospective primary care database analyses.
Rathmann W; Pscherer S; Konrad M; Kostev K
Prim Care Diabetes; 2016 Feb; 10(1):36-40. PubMed ID: 25937183
[TBL] [Abstract][Full Text] [Related]
4. Older people with Type 2 diabetes, including those with chronic kidney disease or dementia, are commonly overtreated with sulfonylurea or insulin therapies.
Hambling CE; Seidu SI; Davies MJ; Khunti K
Diabet Med; 2017 Sep; 34(9):1219-1227. PubMed ID: 28498634
[TBL] [Abstract][Full Text] [Related]
5. Antidiabetic prescriptions and glycemic control in German patients with type 2 diabetes mellitus: a retrospective database study.
Yurgin N; Secnik K; Lage MJ
Clin Ther; 2007 Feb; 29(2):316-25. PubMed ID: 17472823
[TBL] [Abstract][Full Text] [Related]
6. Time to Insulin Initiation in Type 2 Diabetes Patients in 2010/2011 and 2016/2017 in Germany.
Kostev K; Gölz S; Scholz BM; Kaiser M; Pscherer S
J Diabetes Sci Technol; 2019 Nov; 13(6):1129-1134. PubMed ID: 30862186
[TBL] [Abstract][Full Text] [Related]
7. Sodium-glucose co-transporter-2 inhibitors, the latest residents on the block: Impact on glycaemic control at a general practice level in England.
Heald AH; Fryer AA; Anderson SG; Livingston M; Lunt M; Davies M; Moreno GYC; Gadsby R; Young RJ; Stedman M
Diabetes Obes Metab; 2018 Jul; 20(7):1659-1669. PubMed ID: 29516618
[TBL] [Abstract][Full Text] [Related]
8. Prescription Patterns and the Cost of Antihyperglycemic Drugs in Patients With Type 2 Diabetes Mellitus in Germany.
Jacob L; von Vultee C; Kostev K
J Diabetes Sci Technol; 2017 Jan; 11(1):123-127. PubMed ID: 27402240
[TBL] [Abstract][Full Text] [Related]
9. Predictors and consequences of declining insulin therapy by individuals with type 2 diabetes.
Turchin A; Hosomura N; Zhang H; Malmasi S; Shubina M
Diabet Med; 2020 May; 37(5):814-821. PubMed ID: 32077139
[TBL] [Abstract][Full Text] [Related]
10. Prescription Patterns and Disease Control in Type 2 Diabetes Mellitus Patients in Nursing Home and Home Care Settings: A Retrospective Analysis in Germany.
Kostev K; Rockel T; Jacob L
J Diabetes Sci Technol; 2018 Jan; 12(1):136-139. PubMed ID: 28539088
[TBL] [Abstract][Full Text] [Related]
11. Treatment Patterns in Patients With Newly Diagnosed Type 2 Diabetes in China: A Retrospective, Longitudinal Database Study.
Wang C; Gao Y; Zhu L; Huang M; Wu Y; Xuan J
Clin Ther; 2019 Aug; 41(8):1440-1452. PubMed ID: 31155146
[TBL] [Abstract][Full Text] [Related]
12. Clinical inertia with regard to intensifying therapy in people with type 2 diabetes treated with basal insulin.
Khunti K; Nikolajsen A; Thorsted BL; Andersen M; Davies MJ; Paul SK
Diabetes Obes Metab; 2016 Apr; 18(4):401-9. PubMed ID: 26743666
[TBL] [Abstract][Full Text] [Related]
13. Changes in time to insulin initiation in type 2 diabetes patients: a retrospective database analysis in Germany and UK (2005-2010).
Kostev K; Rathmann W
Prim Care Diabetes; 2013 Oct; 7(3):229-33. PubMed ID: 23608219
[TBL] [Abstract][Full Text] [Related]
14. Factors associated with Prolonged Inaction in the hypoglycaemic treatment in people with non-insulin dependent Type 2 Diabetes and elevated glycated haemoglobin: A registry-based cohort study.
Goderis G; Vaes B; Van den Akker M; Elli S; Mathieu C; Buntinx F; Henrard S
Prim Care Diabetes; 2017 Oct; 11(5):482-489. PubMed ID: 28648964
[TBL] [Abstract][Full Text] [Related]
15. Route to improving Type 1 diabetes mellitus glycaemic outcomes: real-world evidence taken from the National Diabetes Audit.
Heald AH; Livingston M; Fryer A; Moreno GYC; Malipatil N; Gadsby R; Ollier W; Lunt M; Stedman M; Young RJ
Diabet Med; 2018 Jan; 35(1):63-71. PubMed ID: 29120503
[TBL] [Abstract][Full Text] [Related]
16. Characteristics Associated with the Choice of First Injectable Therapy Among US Patients With Type 2 Diabetes.
Yu M; Mody R; Landó LF; Shui A; Kallenbach L; Slipski L; de Oliveira CP
Clin Ther; 2017 Dec; 39(12):2399-2408. PubMed ID: 29196084
[TBL] [Abstract][Full Text] [Related]
17. Change in glycated haemoglobin levels after initiating second-line therapy in type 2 diabetes: a primary care database study.
Rathmann W; Bongaerts B; Kostev K
Diabetes Obes Metab; 2016 Aug; 18(8):840-3. PubMed ID: 27062643
[TBL] [Abstract][Full Text] [Related]
18. Longitudinal change in HbA1c in patients with type 2 diabetes: comparison of short-acting, biphasic and basal insulin.
Rathmann W; Strassburger K; Kostev K; Schröder-Bernhardi D; Giani G; Happich M
Exp Clin Endocrinol Diabetes; 2009 May; 117(5):230-3. PubMed ID: 19226479
[TBL] [Abstract][Full Text] [Related]
19. Lower incidence of recorded cardiovascular outcomes in patients with type 2 diabetes using insulin aspart vs. those on human regular insulin: observational evidence from general practices.
Rathmann W; Kostev K
Diabetes Obes Metab; 2013 Apr; 15(4):358-63. PubMed ID: 23137345
[TBL] [Abstract][Full Text] [Related]
20. Individualised targets for insulin initiation in type 2 diabetes mellitus-the influence of physician and practice: a cross-sectional study in eight European countries.
Boels AM; Koning E; Vos RC; Khunti K; Rutten GE
BMJ Open; 2019 Aug; 9(8):e032040. PubMed ID: 31455718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
